Beneficial Effect of Efonidipine, an L- and T-Type Dual Calcium Channel Blocker, on Heart Rate and Blood Pressure in Patients With Mild-to-Moderate Essential Hypertension

Background and Objectives: Efonidipine hydrochloride, an L- and T-type dual calcium channel blocker, is suggested to have a heart rate (HR)-slowing action in addition to a blood pressure (BP)-lowering effect. The aim of this study was to determine the effect of efonidipine on HR and BP in patients with mild-to-moderate hypertension. Subjects and Methods: In a multi-center, prospective, open-labeled, single-armed study, we enrolled 53 patients who had mild-to-moderate hypertension {sitting diastolic BP (SiDBP) 90-110 mmHg}. After a 2-week washout, eligible patients were treated with efonidipine (40 mg once daily for 12 weeks). The primary end point was the change in HR from baseline to week 12. The secondary end-point included the change in trough sitting BP and 24-hour mean BP between baseline and week 12. Laboratory and clinical adverse events were monitored at each study visit (4, 8, and 12 weeks). Results: Fifty-two patients were included in the intention-to-treat analysis. After 12 weeks of treatment with efonidipine, the resting HR decreased significantly from baseline to week 12 (from 81.5??5.3 to 71.8??9.9 beats/minute (difference, -9.9??9.0 beats/minute), p<0.0001}. The trough BP {sitting systolic blood pressure (SiSBP) and SiDBP} and 24-hour mean BP also decreased significantly (SiSBP: from 144.6??8.2 to 132.9??13.5 mmHg, p<0.0001; SiDBP: from 96.9??5.4 to 88.3??8.6 mmHg, p<0.0001, 24-hour mean systolic BP: from 140.4??13.5 to 133.8??11.6 mmHg, p<0.0001; 24-hour mean diastolic BP: from 91.7??8.7 to 87.5??9.5 mmHg, p<0.0001). Conclusion: Efonidipine was effective in controlling both HR and BP in patients with mild-to-moderate hypertension. Copyright ?? 2010 The Korean Society of Cardiology

Combined effects of aerobic exercise and 40-Hz light flicker exposure on early cognitive impairments in Alzheimer’s disease of 3×Tg mice

Alzheimer’s disease (AD) is a progressive degenerative brain disease and the primary cause of dementia. At an early stage, AD is generally characterized by short-term memory impairment, owing to dysfunctions of the cortex and hippocampus. We previously reported that a combination of exercise and 40-Hz light flickering can protect against AD-related neuroinflammation, gamma oscillations, reduction in Aβ, and cognitive decline. Therefore, we sought to extend our previous findings to the 5-mo-old 3×Tg-AD mouse model to examine whether the same favorable effects occur in earlier stages of cognitive dysfunction. We investigated the effects of 12 wk of exercise combined with 40-Hz light flickering on cognitive function by analyzing neuroinflammation, mitochondrial function, and neuroplasticity in the hippocampus in a 3×Tg-AD mouse model. Five-month-old 3×Tg-AD mice performed 12 wk of exercise with 40-Hz light flickering administered independently and in combination. Spatial learning and memory, long-term memory, hippocampal Aβ, tau, neuroinflammation, proinflammatory cytokine expression, mitochondrial function, and neuroplasticity were analyzed. Aβ and tau proteins levels were significantly reduced in the early stage of AD, resulting in protection against cognitive decline by reducing neuroinflammation and proinflammatory cytokines. Furthermore, mitochondrial function improved, apoptosis was reduced, and synapse-related protein expression increased. Overall, exercise with 40-Hz light flickering was significantly more effective than exercise or 40-Hz light flickering alone, and the improvement was comparable to the levels in the nontransgenic aged-match control group. Our results indicate a synergistic effect of exercise and 40-Hz light flickering on pathological improvements in the hippocampus during early AD-associated cognitive impairment

Evaluation of 28 Human Embryonic Stem Cell Lines for Use as Unrelated Donors in Stem Cell Therapy: Implications of HLA and ABO Genotypes

For human embryonic stem cells (hESCs) to be used clinically, it is imperative that immune responses evoked by hESCs and their derivates after transplantation should be prevented. Human leukocyte antigens (HLA) and ABO blood group antigens are important histocompatibility factors in graft rejection. HLA matching between recipient and unrelated donors, in particular, is important in improving outcomes in hematopoietic cell transplantation (HCT). We have established and successfully maintained 29 hESC lines and analyzed the HLA and ABO genotypes of these lines. HLA-A, -B, -C and -DR (DRB1) genotyping was performed by polymerase chain reaction (PCR) sequence-based typing and ABO genotyping was carried out by PCR restriction fragment length polymorphism methods. To determine what proportion of the Korean population would be covered by these cell lines in organ transplantation, 27 cell lines with HLA-A, -B, and -DR data were evaluated for HCT (cord blood) donors and 28 cell lines with HLA-DR and ABO data were evaluated for solid organ (kidney) transplantation donors, and then compared the data with those from 6,740 donated cord bloods. When <= 2 HLA mismatches are allowed for HCT, as currently accepted for cord blood transplantation, it was estimated that about 16% and 25% of the possible recipients can find one or more donor cell lines with mismatches at A, B, DRB1 allele level and at A, B antigen/DRB1 allele level, respectively. When HLA-DR antigen level matching and ABO compatibility was considered for solid organ (kidney) transplantation, it was estimated that about 29% and 96% of the possible recipients can find one or more ABO-compatible donor cell lines with 0 and 1 DR mismatches, respectively. We provided the first report on the HLA and ABO genotypes of hESC lines, and estimated the degree of HLA and ABO matching in organ transplantation for the Korean population.Yu JY, 2009, SCIENCE, V324, P797, DOI 10.1126/science.1172482Kaji K, 2009, NATURE, V458, P771, DOI 10.1038/nature07864Lee JY, 2010, FERTIL STERIL, V93, P976, DOI 10.1016/j.fertnstert.2008.10.017Holdsworth R, 2009, TISSUE ANTIGENS, V73, P95, DOI 10.1111/j.1399-0039.2008.01183.xLehec SC, 2009, CELL TRANSPLANT, V18, P941, DOI 10.3727/096368909X471323Oishi K, 2009, CELL TRANSPLANT, V18, P581Molne J, 2008, TRANSPLANTATION, V86, P1407, DOI 10.1097/TP.0b013e31818a6805Fernandes AM, 2010, CELL TRANSPLANT, V19, P509, DOI 10.3727/096368909X485067Stadtfeld M, 2008, SCIENCE, V322, P945, DOI 10.1126/science.1162494Wang GW, 2005, BIOCHEM BIOPH RES CO, V330, P934, DOI 10.1016/j.bbrc.2005.03.058Hoffman LM, 2005, NAT BIOTECHNOL, V23, P699, DOI 10.1038/nbt1102Li Y, 2005, BIOTECHNOL BIOENG, V91, P688, DOI 10.1002/bit.20536Vallier L, 2005, J CELL SCI, V118, P4495, DOI 10.1242/jcs.02553Taylor CJ, 2005, LANCET, V366, P2019Boyd AS, 2005, ADV DRUG DELIVER REV, V57, P1944, DOI 10.1016/j.addr.2005.08.004Ludwig TE, 2006, NAT BIOTECHNOL, V24, P185, DOI 10.1038/nbt1177Drukker M, 2006, STEM CELLS, V24, P221, DOI 10.1634/stemcells.2005-0188Priddle H, 2006, STEM CELLS, V24, P815, DOI 10.1634/stemcells.2005-0356Reubinoff BE, 2000, NAT BIOTECHNOL, V18, P399Amit M, 2000, DEV BIOL, V227, P271Xu CH, 2001, NAT BIOTECHNOL, V19, P971Drukker M, 2002, P NATL ACAD SCI USA, V99, P9864, DOI 10.1073/pnas.142298299Richards M, 2002, NAT BIOTECHNOL, V20, P933, DOI 10.1038/nbt726Bradley JA, 2002, NAT REV IMMUNOL, V2, P859, DOI 10.1038/nri934Amit M, 2003, BIOL REPROD, V68, P2150, DOI 10.1095/biolreprod.102.012583Li L, 2004, STEM CELLS, V22, P448Drukker M, 2004, TRENDS BIOTECHNOL, V22, P136, DOI 10.1016/j.tibtech.2004.01.003Thomson JA, 1998, SCIENCE, V282, P1145Petersdorf EW, 1999, CURR OPIN IMMUNOL, V11, P521Bodnar MS, 2004, STEM CELLS DEV, V13, P243Koivisto H, 2004, REPROD BIOMED ONLINE, V9, P330Rocha V, 2004, NEW ENGL J MED, V351, P2276Laughlin MJ, 2004, NEW ENGL J MED, V351, P2265Lee JB, 2005, BIOL REPROD, V72, P42, DOI 10.1095/biolrepod.104.033480Xu RH, 2005, NAT METHODS, V2, P185, DOI 10.1038/NMETH744Beattie GM, 2005, STEM CELLS, V23, P489, DOI 10.1634/stemcells.2004-0279Genbacev O, 2005, FERTIL STERIL, V83, P1517, DOI 10.1016/j.fertnstert.2005.01.086Oh SKW, 2006, CLIN EXP PHARMACOL P, V33, P489Skottman H, 2006, FEBS LETT, V580, P2875, DOI 10.1016/j.febslet.2006.03.083Xiao L, 2006, STEM CELLS, V24, P1476, DOI 10.1634/stemcells.2005-0299Stussi G, 2006, TRANSFUS APHER SCI, V35, P59, DOI 10.1016/j.transci.2006.05.009Takahashi K, 2006, CELL, V126, P663Guhr A, 2006, STEM CELLS, V24, P2187, DOI 10.1634/stemcells.2006-0053Klumpp TR, 2006, BONE MARROW TRANSPL, V38, P615, DOI 10.1038/sj.bmt.1705496Nakajima F, 2007, STEM CELLS, V25, P983, DOI 10.1634/stemcells.2006-0566Huangfu DW, 2008, NAT BIOTECHNOL, V26, P1269, DOI 10.1038/nbt.1502Petersdorf EW, 2008, CURR OPIN IMMUNOL, V20, P588, DOI 10.1016/j.coi.2008.06.014Chen YT, 2008, STEM CELLS DEV, V17, P853, DOI 10.1089/scd.2007.0226Park IH, 2008, CELL, V134, P877, DOI 10.1016/j.cell.2008.07.041Swijnenburg RJ, 2008, P NATL ACAD SCI USA, V105, P12991, DOI 10.1073/pnas.0805802105Unger C, 2008, HUM MOL GENET, V17, pR48, DOI 10.1093/hmg/ddn079Drukker M, 2008, SEMIN IMMUNOL, V20, P123, DOI 10.1016/j.smim.2007.11.002Revazova ES, 2008, CLONING STEM CELLS, V10, P11, DOI 10.1089/clo.2007.0063Mountford JC, 2008, TRANSFUSION MED, V18, P1, DOI 10.1111/j.1365-3148.2007.00807.xPark IH, 2008, NATURE, V451, P141, DOI 10.1038/nature06534Nakagawa M, 2008, NAT BIOTECHNOL, V26, P101, DOI 10.1038/nbt1374Buzzeo MP, 2008, CELL TRANSPLANT, V17, P489Kamani N, 2008, BIOL BLOOD MARROW TR, V14, P1, DOI 10.1016/j.bbmt.2007.11.003Saric T, 2008, CELLS TISSUES ORGANS, V188, P78, DOI 10.1159/000118784Navarro-Alvarez N, 2008, CELL TRANSPLANT, V17, P27KASTENBERG ZJ, 2008, TRANSPLANT REV ORLAN, V22, P215Lee SJ, 2007, BLOOD, V110, P4576, DOI 10.1182/blood-2007-06-097386Shaw BE, 2007, BLOOD, V110, P4560, DOI 10.1182/blood-2007-06-095265Strom S, 2007, HUM REPROD, V22, P3051, DOI 10.1093/humep/dem35Lin G, 2007, CELL RES, V17, P999, DOI 10.1038/cr.2007.97Crook JM, 2007, CELL STEM CELL, V1, P490Helming AM, 2007, PEDIATR BLOOD CANCER, V49, P313, DOI 10.1002/pbc.21025Cabrera CM, 2007, CELL BIOL INT, V31, P1072, DOI 10.1016/j.cellbi.2007.03.015Lei T, 2007, CELL RES, V17, P682, DOI 10.1038/cr.2007.61Okita K, 2007, NATURE, V448, P313, DOI 10.1038/nature05934Wernig M, 2007, NATURE, V448, P318, DOI 10.1038/nature05944Maherali N, 2007, CELL STEM CELL, V1, P55, DOI 10.1016/j.stem.2007.05.014Eapen M, 2007, LANCET, V369, P1947

A Case of Allergic Contact Dermatitis Due to DuoDERM Extrathin®

Over the past years, hydrocolloid dressings have been introduced routinely in the treatment of various types of wounds. They provide a moist environment promoting autolytic debridement, and stimulate angiogenesis. However, long-term application often leads to inflammation of the skin in the immediate area of the ulcer, causing irritant dermatitis in many cases, but sometimes also leads to contact sensitization. A 32 year-old woman burnt herself by an iron, and presented to our clinic and was treated with Duoderm extrathin®. Nine days later, she again presented with an erythematous oozing patch with edema, and allergic contact dermatitis was suspected. A patch test (TRUE test) was performed and a positive reaction to colophonium was obtained. Duoderm extrathin® contains hydrogenated rosin (colophonium) as the tackifying agent, so we could diagnose this case as allergic contact dermatitis due to the hydrogenated rosin in Duoderm extrathin®. We report another case of allergic contact dermatitis due to Duoderm extrathin® in a 32 year-old woman

Platelet-activating Factor–mediated NF-κB Dependency of a Late Anaphylactic Reaction

Anaphylaxis is a life-threatening systemic allergic reaction with the potential for a recurrent or biphasic pattern. Despite an incidence of biphasic reaction between 5 and 20%, the molecular mechanism for the reaction is unknown. Using a murine model of penicillin V–induced systemic anaphylaxis, we show an autoregulatory cascade of biphasic anaphylactic reactions. Induction of anaphylaxis caused a rapid increase in circulating platelet-activating factor (PAF) levels. In turn, the elevated PAF contributes to the early phase of anaphylaxis as well as the subsequent activation of the nuclear factor (NF)-κB, a crucial transcription factor regulating the expression of many proinflammatory cytokines and immunoregulatory molecules. The induction of NF-κB activity is accompanied by TNF-α production, which, in turn, promotes late phase PAF synthesis. This secondary wave of PAF production leads eventually to the late phase of anaphylactic reactions. Mast cells do not appear to be required for development of the late phase anaphylaxis. Together, this work reveals the first mechanistic basis for biphasic anaphylactic reactions and provides possible therapeutic strategies for human anaphylaxis

Analysis of Swine Leukocyte Antigen Haplotypes in Yucatan Miniature Pigs Used as Biomedical Model Animal

The porcine major histocompatibility complex (MHC) is called swine leukocyte antigen (SLA), which controls immune responses and transplantation reactions. The SLA is mapped on pig chromosome 7 (SSC7) near the centromere. In this study, 3 class I (SLA-1, SLA-3, and SLA-2) and 3 class II (DRB1, DQB1, and DQA) genes were used for investigation of SLA haplotypes in Yucatan miniature pigs in Korea. This pig breed is a well-known model organism for biomedical research worldwide. The current study indicated that Korean Yucatan pig population had 3 Class I haplotypes (Lr-4.0, Lr-6.0, and Lr-25.0) and 3 class II haplotypes (Lr-0.5, Lr-0.7, and Lr-0.25). The combinations of SLA class I and II haplotype together, 2 homozygous (Lr-4.5/4.5 and Lr-6.7/6.7) and 3 heterozygous (Lr-4.5/6.7, Lr-4.5/25.25, and Lr-6.7/25.25) haplotypes were identified, including previously unidentified new heterozygous haplotypes (Lr-4.5/4.7). In addition, a new SLA allele typing method using Agilent 2100 bioanalyzer was developed that permitted more rapid identification of SLA haplotypes. These results will facilitate the breeding of SLA homozygous Yucatan pigs and will expedite the possible use of these pigs for the biomedical research, especially xenotransplantation research